SPARTANTON, Va.

— The Virginia Tech University researchers who helped engineer a chemical that is one of the most powerful drugs in the world to combat malaria have found an effective way to use the drug to treat people with severe chronic fatigue syndrome.

The breakthrough was reported Wednesday in a scientific journal published in the American Journal of Medicine.

The study is the first to show a drug that blocks an enzyme that leads to a buildup of sugar, and the first of its kind to show an effect lasting up to three weeks.

The drug, called ritonavir, also has a potential for treating severe fatigue syndrome and other autoimmune disorders.

“We’ve shown that the drug does have a long-term effect in people with chronic fatigue, but it doesn’t have any effects on people with other chronic diseases,” said senior author Daniel L. Stober, PhD, professor of medical biochemistry and molecular genetics at the University of Virginia.

“We’re trying to figure out how to use this drug to make a cure for a disease that’s already been diagnosed.”

Stober and his team have been developing the drug since late 2016, when they used it to help treat chronic fatigue in adults with chronic pain.

The compound they created also is able to be used to treat other diseases, such as hepatitis C and HIV.

“Our study shows that this compound, when given as a combination with other drugs, is an effective treatment for people with COPD, but we haven’t shown that it’s effective for people without COPD,” Stober said.

In a controlled clinical trial, Stober’s team showed that people with the chronic fatigue disease who received ritonabir also experienced improvements in their quality of life and their overall quality of their lives.

In one of three trials, those who took the drug experienced an increase in physical activity, which is an important component of long-lasting physical activity.

“The drug is an excellent treatment, because it is very effective at reducing pain and fatigue,” Stber said.

“People who take it get the most benefit and don’t get any side effects, and it doesn.

But we’ve shown it’s a drug for people who are already sick, and we don’t know if it will be as effective for others.”

For the first three weeks, the drug was given to two dozen people in a controlled trial at the Virginia Tech Research Institute.

During that period, the scientists monitored the progress of the drug in more than 70 patients and compared them to those who had never received rionavir.

The two groups, which were given the drug on a daily basis, also did their physical activity tests, and researchers monitored the levels of a protein that is important in regulating inflammation in the body called the CRP.

The researchers found that the patients with chronic and severe fatigue who received the drug had significantly lower levels of CRP, and they also had significantly higher levels of the protein that regulates inflammation in their bodies.

“It turns out that when people have chronic fatigue and have high levels of inflammation in many different areas of their body, that increases the production of inflammatory molecules,” Staber said.

The researchers also found that when they gave the drug orally to those with severe fatigue and chronic inflammation, they experienced a reduction in pain and the severity of their symptoms, although that wasn’t the case for those who didn’t receive rionabir.

“That is, it was an improvement,” Stberger said.

Stober said he and his colleagues have been working on developing a similar drug that can be used for the treatment of patients with COPDS and other chronic conditions.

“This is a really important study that shows that the compound that we developed and that we are using now has a very good safety profile,” he said.

Stberger and his research team are also working on other possible treatments for chronic fatigue.

Tags: